title: Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells.
abstract: Pluripotent stem cells hold great promises for regenerative medicine. They might become useful as a universal source for a battery of new cell replacement therapies. Among the major concerns for the clinical application of stem cell-derived grafts are the risks of immune rejection and tumor formation. Pluripotency and tumorigenicity are closely linked features of pluripotent stem cells. However, the capacity to form teratomas or other tumors is not sufficiently described by inherited features of a stem cell line or a stem cell-derived graft. The tumorigenicity always depends on the inability of the recipient to reject the tumorigenic cells. This review summarizes recent data on the tumorigenicity of pluripotent stem cells in immunodeficient, syngeneic, allogeneic, and xenogeneic hosts. The effects of immunosuppressive treatment and cell differentiation are discussed. Different immune effector mechanisms appear to be involved in the rejection of undifferentiated and differentiated cell populations. Elements of the innate immune system, such as natural killer cells and the complement system, which are active also in syngeneic recipients, appear to preferentially reject undifferentiated cells. This effect could reduce the risk of tumor formation in immunocompetent recipients. Cell differentiation apparently increases susceptibility to rejection by the adaptive immune system in allogeneic hosts. The current data suggest that the immune system of the recipient has a major impact on the outcome of pluripotent stem cell transplantation, whether it is rejection, engraftment, or tumor development. This has to be considered when the results of experimental transplantation models are interpreted and even more when translation into clinics is planned.
authors.affiliation: Department of Cellular and Molecular Immunology, University of Göttingen, Humboldtallee 34, 37073, Göttingen, Germany. rdresse@gwdg.de
authors.forename: Ralf
authors.initials: R
authors.lastname: Dressel
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D002471:Cell Transformation, Neoplastic / Q000276:immunology* / Q000378:metabolism; D006648:Histocompatibility / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host / Q000235:genetics / Q000276:immunology; D007157:Immunologic Surveillance; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D039904:Pluripotent Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D044968:Regenerative Medicine; D018570:Risk Assessment; D033581:Stem Cell Transplantation; D013724:Teratoma / Q000276:immunology
chemical_list: D007166:Immunosuppressive Agents